--Mesoblast, global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration on items required for filing a ...

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure Provided by GlobeNewswire Jun 30, 2025, 5:36:48 PM ...

Latest medical research on lung disease. Learn about the symptoms of chronic obstructive pulmonary disease (COPD), emphysema, and lung cancer along with the latest treatment information.